Posts tagged: optica

Research Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.

Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica Ingo Kleiter, MD; Kerstin Hellwig, MD; Achim Berthele, MD; Tania K?mpfel, MD; Ralf A. Linker, MD; Hans-Peter Hartung, MD; Friedemann Paul, MD; Orhan Aktas, MD; for the Neuromyelitis Optica Study Group Arch Neurol. ?2012;69(2):239-245.

Vitamin D was significantly lower in people with recurrent transverse myelitis, neuromyelitis optica, and related inflammatory spinal diseases, researchers found. On the other hand, there appears to be no link between the vitamin and idiopathic transverse myelitis, which does not recur, according to Michael Levy, MD, PhD, of Johns Hopkins University, and colleagues. The finding, from a retrospective analysis, is reminiscent of what has been seen in multiple sclerosis and other recurrent autoimmune illnesses, and may provide clues to the role vitamin D plays in immune regulation, Levy and colleagues argued online in Archives of Neurology .

Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years Su-Hyun Kim, MD; Woojun Kim, MD, PhD; Xue Feng Li, MD, MSc; In-Ja Jung, RN; Ho Jin Kim, MD, PhD Arch Neurol. ?2011;68(11):1412-1420. doi:10.1001/archneurol.2011.154 Objective? To evaluate the efficacy and safety of repeated rituximab treatment based on the assessment of peripheral circulating memory B cells over 24 months in patients with relapsing neuromyelitis optica (NMO).

Neuromyelitis optica in Japanese sisters.

J Neuroimmunol. 2011 Jul;236(1-2):81-6. Epub 2011 May 31.

Sudhakar Reddy Kalluri 1 , Veit Rothhammer 1 , Ori Staszewski 2 , Rajneesh Srivastava 1 , Franziska Petermann 1 , Marco Prinz 2 , Bernhard Hemmer 1 , Thomas Korn 1 * 1 Department of Neurology, Klinikum rechts der Isar, Technische Universit?t M?nchen, M?nchen, Germany, 2 Department of Neuropathology, Institute of Pathology, Universit?tsklinikum Freiburg, Freiburg, Germany Abstract? Background Antibodies to the water channel protein aquaporin-4 (AQP4), which is expressed in astrocytic endfeet at the blood brain barrier, have been identified in the serum of Neuromyelitis optica (NMO) patients and are believed to induce damage to astrocytes. However, AQP4 specific T helper cell responses that are required for the generation of anti-AQP4 antibodies and most likely also for the formation of intraparenchymal CNS lesions have not been characterized.

Genetic analysis of aquaporin-4 in neuromyelitis optica. Matiello M , Schaefer-Klein JL , Hebrink DD , Kingsbury DJ , Atkinson EJ , Weinshenker BG ; On behalf of the NMO Genetics Collaborators

Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Costanzi C , Matiello M , Lucchinetti CF , Weinshenker BG , Pittock SJ , Mandrekar J , Thapa P , McKeon A .

Markedly Elevated Soluble Intercellular Adhesion Molecule 1, Soluble Vascular Cell Adhesion Molecule 1 Levels, and Blood-Brain Barrier Breakdown in Neuromyelitis Optica Akiyuki Uzawa, MD; Masahiro Mori, MD, PhD; Saeko Masuda, MD; Satoshi Kuwabara, MD, PhD Arch Neurol. ?2011;68(7):913-917.

Pathogenic T cell responses against aquaporin 4. Pohl M , Fischer MT , Mader S , Schanda K , Kitic M , Sharma R , Wimmer I , Misu T , Fujihara K , Reindl M , Lassmann H , Bradl M . Source Department of Neuroimmunology, Center for Brain Research, Medical University Vienna, Spitalgasse 4, 1090, Vienna, Austria.